Drug Trial Radar · NCT07606599
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
398
Planned (sponsor's estimate)
Start
Jul 7, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- May 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after platinum-containing chemotherapy failure.
Conditions
- Biliary Tract Cancer
Interventions
BL-M07D1Drug
Administration by intravenous infusion for a cycle of 3 weeks.
OxaliplatinDrug
Administration by intravenous infusion for a cycle of 2 weeks.
Calcium levofolinateDrug
Administration by intravenous infusion for a cycle of 2 weeks.
FluorouracilDrug
Administration by intravenous infusion for a cycle of 2 weeks.
Irinotecan Hydrochloride LiposomeDrug
Administration by intravenous infusion for a cycle of 2 weeks.
Irinotecan HydrochlorideDrug
Administration by intravenous infusion for a cycle of 2 weeks.
Capecitabine TabletsDrug
Oral administration for a cycle of 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.